Candel Therapeutics 2026 annual meeting vote results

Candel Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 23, 2026.

Rhea-AI Filing Summary

Candel Therapeutics, Inc. reported the results of its Annual Meeting of Stockholders held on June 23, 2026. As of April 24, 2026, there were 73,270,239 outstanding shares of voting common stock entitled to vote at the meeting.

Stockholders elected four Class II directors to serve until the 2029 annual meeting: Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci. Support ranged from 24,897,348 to 31,591,618 votes "for," with broker non-votes of 22,175,525 for each nominee.

Stockholders also ratified the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, with 53,543,020 votes for, 238,508 against, and 87,967 abstentions. No other matters were submitted for a vote.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares outstanding eligible to vote: 73,270,239 shares Votes for KPMG auditor ratification: 53,543,020 votes Votes against KPMG auditor ratification: 238,508 votes +4 more

7 metrics

Shares outstanding eligible to vote 73,270,239 shares Voting common stock as of record date April 24, 2026

Votes for KPMG auditor ratification 53,543,020 votes Proposal 2, fiscal year ending December 31, 2026

Votes against KPMG auditor ratification 238,508 votes Proposal 2, Annual Meeting on June 23, 2026

Abstentions on auditor ratification 87,967 votes Proposal 2, independent registered public accounting firm

Votes for Paul B. Manning 31,591,618 votes Election as Class II director under Proposal 1

Votes withheld for Edward J. Benz, Jr., M.D. 6,796,622 votes Election as Class II director, Proposal 1

Broker non-votes for director elections 22,175,525 votes Each Class II director nominee under Proposal 1

Key Terms

Annual Meeting of Stockholders, record date, Class II directors, broker non-votes, +1 more

5 terms

Annual Meeting of Stockholders financial

"held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 23, 2026"

record date financial

"As of April 24, 2026, the record date for the Annual Meeting"

The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.

Class II directors financial

"to elect four Class II directors, Edward J. Benz, Jr., M.D., Paul B. Manning"

broker non-votes financial

"The votes cast at the Annual Meeting were as follows ... Broker Non-Votes"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered public accounting firm financial

"to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm"

An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Candel Therapeutics (CADL) stockholders vote on at the 2026 Annual Meeting?

Stockholders voted on electing four Class II directors and ratifying KPMG LLP as independent registered public accounting firm for 2026. These proposals were described in the company’s definitive proxy statement filed April 29, 2026, and both items received the required stockholder approvals.

Who was elected to Candel Therapeutics (CADL) board as Class II directors in 2026?

Stockholders elected Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci as Class II directors. They will serve until the 2029 annual meeting and until their successors are duly elected and qualified, subject to earlier death, resignation, or removal.

How many Candel Therapeutics (CADL) shares were eligible to vote at the 2026 Annual Meeting?

There were 73,270,239 outstanding shares of Candel Therapeutics’ voting common stock as of April 24, 2026, the record date. Only holders of these shares on that date were entitled to vote on the matters presented at the June 23, 2026 Annual Meeting.

What were the vote results for Candel Therapeutics (CADL) auditor ratification in 2026?

The appointment of KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026 received 53,543,020 votes for, 238,508 votes against, and 87,967 abstentions. This outcome reflects stockholder ratification of KPMG’s role as the company’s external auditor for that fiscal year.

How strong was support for Candel Therapeutics (CADL) director nominee Paul B. Manning in 2026?

Director nominee Paul B. Manning received 31,591,618 votes for and 102,352 votes withheld, with 22,175,525 broker non-votes. These results show that a large majority of votes cast by stockholders present or represented at the meeting supported his election to the board.

When was Candel Therapeutics (CADL) 2026 Annual Meeting held and what else was voted?

The Annual Meeting took place on June 23, 2026. Besides electing four Class II directors, stockholders voted on ratifying KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026. No other matters were submitted for a vote at this meeting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/24/2026 - 04:24 PM EDT Learn about SEC filing dates

0001841387false00018413872026-06-232026-06-23

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 23, 2026

CANDEL THERAPEUTICS, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-40629	52-2214851
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
117 Kendrick St Suite 450
Needham, Massachusetts				02494
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (617) 916-5445

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value per share		CADL		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

Candel Therapeutics, Inc., a Delaware corporation (the “Company”), held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 23, 2026. As of April 24, 2026, the record date for the Annual Meeting, there were 73,270,239 outstanding shares of the Company’s voting common stock. The Company’s stockholders voted on the following matters, which are described in detail in the Company’s Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 29, 2026: (i) to elect four Class II directors, Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci, to serve until the Company’s 2029 annual meeting of stockholders and until their successor has been duly elected and qualified, subject to their earlier death, resignation or removal (“Proposal 1”) and (ii) to ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 (“Proposal 2”).

The Company’s stockholders elected each of the Class II director nominees, Edward J. Benz, Jr., M.D., Paul B. Manning, Maha Radhakrishnan, M.D., and Paul Peter Tak, M.D., Ph.D., FMedSci, recommended for election at the Annual Meeting in Proposal 1. The votes cast at the Annual Meeting were as follows:

		For		Withheld		Broker Non-Votes
Edward J. Benz, Jr., M.D.		24,897,348		6,796,622		22,175,525
Paul B. Manning		31,591,618		102,352		22,175,525
Maha Radhakrishnan, M.D.		31,047,706		646,264		22,175,525
Paul Peter Tak, M.D., Ph.D., FMedSci		31,414,668		279,302		22,175,525

The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, recommended for ratification in Proposal 2 at the Annual Meeting. The votes cast at the Annual Meeting were as follows:

For		Against		Abstain
53,543,020		238,508		87,967

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			Candel Therapeutics, Inc.
Date:	June 24, 2026	By:	/s/ Paul Peter Tak
			Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer

Filing Exhibits & Attachments

1 document

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 26.3 KB